New Insight Into Epirubicin Cardiac Toxicity: Competing Risks Analysis of 1097 Breast Cancer Patients - Concepedia

Concepedia

Publication | Open Access

New Insight Into Epirubicin Cardiac Toxicity: Competing Risks Analysis of 1097 Breast Cancer Patients

DOI Full Paper Access

173

Citations

23

References

2008

Year

Marianne Ryberg, Dorte Nielsen, Giuliana Cortese, Gitte Nielsen, Torben Skovsgaard, Per Kragh Andersen

JNCI Journal of the National Cancer Institute

Abstract

Maximum cumulative dosages of epirubicin are presented that confer a 5% risk of cardiotoxicity for patients with different sets of risk factors.

References

	Year	Citations
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure Daniel D. Von Hoff Annals of Internal Medicine Drug SafetyPotential Risk FactorsHeart FailureHealth SciencesCardiovascular Disease	1979	2.4K
Congestive heart failure in patients treated with doxorubicin Sandra M. Swain, Fredrick S. Whaley, Michael S. Ewer Cancer	2003	2.2K
A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer New England Journal of Medicine	2005	1.6K
Long-Term Risk of Cardiovascular Disease in 10-Year Survivors of Breast Cancer Maartje J. Hooning, Akke Botma, Berthe M.P. Aleman, JNCI Journal of the National Cancer Institute	2007	859
Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials Inger Højris, Marie Overgaard, Jens Christensen, The Lancet Surgical OncologyBreast OncologyCardiovascular DiseaseMedicineRandomised Trials	1999	350
Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study John Doyle, Alfred I. Neugut, Judith S. Jacobson, Journal of Clinical Oncology	2005	335
Competing risks as a multi-state model Per Kragh Andersen, Steen Z. Abildstrøm, Susanne Rosthøj Statistical Methods in Medical Research EconomicsReliability EngineeringEngineeringRisk ManagementSafety Science	2002	312
Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. M. Ryberg, Dorte Nielsen, Torben Skovsgaard, Journal of Clinical Oncology	1998	285
A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. K K Jain, E. S. Casper, Nancy L. Geller, Journal of Clinical Oncology Heart FailureBreast OncologyCardiovascular PharmacologyPathologyMultimodality	1985	247
Activation of Rho-associated coiled-coil protein kinase 1 (ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apoptosis Jiang Chang, Min Xie, Viraj Shah, Proceedings of the National Academy of Sciences Caspase-3 CleavageCardiac MuscleHeart FailureApoptosisCell Death	2006	221

Page 1